Search

Your search keyword '"Clappier E"' showing total 236 results

Search Constraints

Start Over You searched for: Author "Clappier E" Remove constraint Author: "Clappier E"
236 results on '"Clappier E"'

Search Results

1. The KMT2A recombinome of acute leukemias in 2023

2. Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION

3. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: APPLICABILITY OF IPSS-M IN MYELODYSPLASTIC SYNDROMES ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

4. GERMLINE CHEK2 MUTATED MDS PATIENTS

5. P087 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: APPLICABILITY OF IPSS-M IN MYELODYSPLASTIC SYNDROMES ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

6. P057 - Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION

8. Dermatose par infiltrat à cellules dendritiques plasmacytoïdes ou indéterminées matures chez des patients atteints d’hémopathie myéloïde, une étude de 14 cas

9. Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

10. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data

11. Granulomatoses cutanées clonales au cours des hémopathies myéloïdes : série de 11 cas

12. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

14. P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY

15. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

16. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

18. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

20. New insights to the MLL recombinome of acute leukemias

21. The KMT2Arecombinome of acute leukemias in 2023

22. The MLL recombinome of acute leukemias in 2017

23. Childhood secondary ALL after ALL treatment

24. Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRβ-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique

27. The MLL recombinome of acute leukemias in 2013

28. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study

29. Impact clinique de la mutation BRAFV600E dans l’histiocytose Langerhansienne pulmonaire de l’adulte

30. B-Cell Acute Lymphoblastic Leukemia (B-ALL) with T (5;14)(Q31;Q32);IGH-IL3 Rearrangement and Eosinophilia: A Peculiar IGH-Rearranged B-ALL

32. Identification de mutations clonales identiques dans les xanthélasma palpébraux de maladie d’Erdheim-Chester associés à des leucémies myélomonocytaires chroniques: à propos de 3 cas

34. PF211 MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL

35. PF257 GEMTUZUMAB OZOGAMICIN COMBINED WITH CYTARABINE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN FIRST RELAPSE

36. PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

37. Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement

38. The MLL recombinome of acute leukemias in 2017

39. The MLL recombinome of acute leukemias in 2017

40. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

41. Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

42. The MLL recombinome of acute leukemias in 2017

43. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling

44. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling

45. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia

46. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol

47. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia

48. The MLL recombinome of acute leukemias in 2013

49. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

Catalog

Books, media, physical & digital resources